



HAL
open science

Modeling Primary Tumor Dynamics of Human-to-Mouse Xenografted Non-Small Cell Lung Cancer in Response to Administration of Bevacizumab and Pemetrexed-Cisplatin

Benjamin Schneider, Arnaud Boyer, Joseph Ciccolini, Kenneth Wang, Martin
E Fernandez-Zapico, Jonathan Paul M. Mochel, Sébastien Benzekry

► **To cite this version:**

Benjamin Schneider, Arnaud Boyer, Joseph Ciccolini, Kenneth Wang, Martin E Fernandez-Zapico, et al.. Modeling Primary Tumor Dynamics of Human-to-Mouse Xenografted Non-Small Cell Lung Cancer in Response to Administration of Bevacizumab and Pemetrexed-Cisplatin. Population Approach Group in Europe (PAGE) Meeting 2018, May 2018, Montreux, Switzerland. 2018. hal-01968942

HAL Id: hal-01968942

<https://inria.hal.science/hal-01968942>

Submitted on 3 Jan 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Modeling Primary Tumor Dynamics of Human-to-Mouse Xenografted Non-Small Cell Cancer in Response to Administration of Bevacizumab and Pemetrexed-Cisplatin

Benjamin K Schneider¹, Arnaud Boyer², Joseph Ciccolini^{2,3}, Kenneth Wang⁴, Martin Fernandez-Zapico⁴, Sebastien Benzekry^{5*}, and Jonathan P Mochel^{1*}

¹Iowa State University College of Veterinary Medicine, Ames, IA, U.S.A.; ²SMARTc Unit, Inserm S_911 CRO2, Aix-Marseille University, Marseille, France; ³Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique Hopitaux de Marseille, Marseille, France; ⁴Mayo Clinic, Rochester, MS, U.S.A.; ⁵French Institute for Research in Computer Science and Automation, Bordeaux, France; *: co-last authors.

IOWA STATE UNIVERSITY
OF SCIENCE AND TECHNOLOGY

Background

- Situation:** Bevacizumab is an anti-angiogenic drug commonly administered concomitantly with chemotherapeutic drugs for advanced non-squamous non-small cell lung cancer (NSCLC). Bevacizumab administration transiently enhances chemotherapeutic drug delivery, resulting in increased efficacy of chemotherapeutic drugs [1].
- Objective:** This analysis attempts to characterize tumor growth dynamics as measured by fluorescence in response to concurrent vs. sequential administration of pemetrexed-cisplatin and bevacizumab in NSCLC tumor carrying mice.

Methods

- Experiment:** Data comes from previous experiment [2] where 77 mice were randomized into 5 treatment groups:
 - control (saline, N=15),
 - beva then pemetrexed-cisplatin after 3 days
 - beva then pemetrexed-cisplatin after 8 days
 - concomitant beva + pemetrexed-cisplatin
 - pemetrexed cisplatin alone
- Statistical Analysis:** Tumor size was evaluated by fluorescence and the resulting data were analyzed using the stochastic approximation expectation maximization algorithm implemented in Monolix 2018 R1. Standard model diagnostics were completed using various R packages as well as other components of the Monolix Suite.




Fig 1: Log-10 observed vs. log-10 individual predictions (spline in yellow). The model least accurately predicts the dynamics of larger tumors. This is in part due to the structure of the measurement error (proportional) but is also due to the relative richness of the data set in smaller tumors.

Results

Fig 2: Adapted Generalized Logistic Growth Model




Fig 3: Control (No Treatment Adm Post Xenograft)




Fig 4: Chemotherapy Only (Bevacizumab Control)




Fig 5: Concomitant Scheduling




Fig 7: Eight Day Scheduling Gap






Fig 6: Three Day Scheduling Gap



In Figure 2, the underlying structural model is depicted. Bevacizumab and the chemotherapeutics are both delayed by parameters τ_A and τ_C respectively before exerting their various effects. The chemotherapeutics inhibit the growth of the tumor while Bevacizumab enhances the action of the chemotherapeutics by transiently increasing vascular quality. The Tumor volume grows at a generalized logistic rate parameterized by α , κ , and ν . The death of the cells damaged by the cytotoxics are modeled via two cell death compartments parameterized by coefficient K .

In Figures 3 through 7 the resulting fit of the model vs the observations for the various treatments on log-10 scale. The vertical error bars are the 50%-IQR on the predictions the model provides (Monte-Carlo simulation with $N = 1000$) while the pink area is the 50%-IQR on the observations. The individual paths of the two data sets are produced by taking the geometric mean of the data at the various time points.

Conclusions and Perspectives



- Our model-based analysis showed that a revisited Logistic (Gompertzian) growth function was predictive for modeling the effect of various scheduling of pemetrexed-cisplatin and bevacizumab in NSCLC tumor carrying mice. The model will further be refined and then used to anticipate the optimal delay between anti-angiogenesis therapy and chemotherapy, and its dependence on the therapeutic dosing schedule.
- Structural identifiability of the model parameters was further confirmed using sensitivity analyses, the estimated correlation of the random effects (<0.10 for most parameters) and the accurate precision of the final model parameters ($RSE < 20\%$). To get this low RSE, some parameters such as ν were fixed to reasonable values. The validity of final model parameter estimates was further confirmed through visual predictive checks using 1000 Monte-Carlo simulations although before publication the numerical value of the estimates will be precisely analyzed.

References [1] Zhao S, Gao F, Zhang Y, Zhang Z, Zhang L. Bevacizumab in combination with different platinum-based doublets in the first-line treatment for advanced nonsquamous non-small-cell lung cancer: A network meta-analysis. *Int J Cancer*. 2018 Apr 15;142(8):1676-1688.

[2] S. Mollard, J. Ciccolini, D.C. Imbs, R. El Cheikh, D. Barbolosi, S. Benzekry *Oncotarget*, Volume 5, 10.18632/oncotarget.15484, 2017